Hims & Hers Health Inc. stock jumped 14%, extending a week-long rally of over 73%, after Barclays said investors are underestimating growth from new products. The firm raised its price target to $29 as the company partnership with Novo Nordisk removes legal uncertainty and expands opportunities in weight-loss drugs.